Skip to Main content Skip to Navigation
Journal articles

Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus

Abstract : The global, randomized, double-blind, phase 3 KEYNOTE-189 study(NCT02578680) showed significantly improved OS and PFS with pembrolizumab(pembro)þpemetrexed (pem)þplatinum compared with placeboþpemþplatinumwith a manageable safety profile in pts with previously untreated metastatic nonsqua-mous NSCLC without targetable EGFR/ALK aberrationsj. We present safety and toler-ability data from Japanese pts enrolled in KEYNOTE-189
Document type :
Journal articles
Complete list of metadatas

Cited literature [4 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02470585
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, March 24, 2020 - 10:29:32 AM
Last modification on : Thursday, April 9, 2020 - 11:53:48 AM
Long-term archiving on: : Thursday, June 25, 2020 - 1:13:12 PM

File

Le Tallec-2020-Eosinophilic fa...
Files produced by the author(s)

Identifiers

Citation

Erwan Le Tallec, Alain Lescoat, Alice Ballerie, Berengere Cador, Hervé Lena, et al.. Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus. Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2020, 15 (2), pp.E29-E30. ⟨10.1016/j.jtho.2019.09.011⟩. ⟨hal-02470585⟩

Share

Metrics

Record views

300

Files downloads

157